Preclinical pharmacokinetics of a novel anti-c-Met antibody–drug conjugate, SHR-A1403, in rodents and non-human primates

References

• Alley SC, Zhang X, Okeley NM, et al. (2009). The pharmacologic basis for antibody-auristatin conjugate activity. J Pharmacol Exp Ther 330:932–8.
   PubMed Web of Science ®Google Scholar
• Almhanna K, Miron ML, Wright D, et al. (2017). Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C. Investig New Drugs 35:235–41.
   PubMed Web of Science ®Google Scholar
• Bahrami A, Shahidsales S, Khazaei M, et al. (2017). C-Met as a potential target for the treatment of gastrointestinal cancer: current status and future perspectives. J Cell Physiol 232:2657–73.
   PubMed Web of Science ®Google Scholar
• Barisione G, Fabbi M, Gino A, et al. (2015). Potential role of soluble c-Met as a new candidate biomarker of metastatic uveal melanoma. JAMA Ophthalmol 133:1013–21.
   PubMed Web of Science ®Google Scholar
• Carrasco-Triguero M, Yi JH, Dere R, et al. (2013). Immunogenicity assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine. Bioanalysis 5:1007–23.
   PubMed Web of Science ®Google Scholar
• Chalouni C, Doll S. (2018). Fate of antibody-drug conjugates in cancer cells. J Exp Clin Cancer Res 37:20–31.
   PubMed Web of Science ®Google Scholar
• Cohen R, Vugts DJ, Visser GW, et al. (2014). Development of novel ADCs: conjugation of tubulysin analogues to trastuzumab monitored by dual radiolabeling. Cancer Res 74:5700–10.
   PubMed Web of Science ®Google Scholar
• Conner KP, Rock BM, Kwon GK, et al. (2014). Evaluation of near infrared fluorescent labeling of monoclonal antibodies as a tool for tissue distribution. Drug Metab Dispos 42:1906–13.
   PubMedGoogle Scholar
• Dan N, Setua S, Kashyap VK, et al. (2018). Antibody-drug conjugates for cancer therapy: chemistry to clinical implications. Pharmaceuticals (Basel) 11:32–53.
   PubMedGoogle Scholar
• Erickson HK, Lambert JM. (2012). ADME of antibody-maytansinoid conjugates. AAPS J 14:799–05.
   PubMed Web of Science ®Google Scholar
• Gao HF, Li AN, Yang JJ, et al. (2017). Soluble c-Met levels correlated with tissue c-Met protein expression in patients with advanced non-small-cell lung cancer. Clin Lung Cancer 18:85–91.
   PubMed Web of Science ®Google Scholar
• Gao HF, Yang JJ, Chen ZH, et al. (2016). Plasma dynamic monitoring of soluble c-Met level for EGFR-TKI treatment in advanced non-small cell lung cancer. Oncotarget 7:39535–43.
   PubMedGoogle Scholar
• Garber K. (2014). MET inhibitors start on road to recovery. Nat Rev Drug Discov 13:563–5.
   PubMed Web of Science ®Google Scholar
• Gow CH, Hsieh MS, Wu SG, et al. (2017). A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population. Lung Cancer 103:82–9.
   PubMed Web of Science ®Google Scholar
• Granito A, Guidetti E, Gramantieri L. (2015). c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma. J Hepatocell Carcinoma 2:29–38.
   PubMed Web of Science ®Google Scholar
• Hock MB, Thudium KE, Carrasco-Triguero M, et al. (2015). Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality. AAPS J 17:35–43.
   PubMed Web of Science ®Google Scholar
• Kalim M, Chen J, Wang S, et al. (2017). Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates. Drug Des Devel Ther 11:2265–76.
   PubMed Web of Science ®Google Scholar
• Leal M, Wentland J, Han X, et al. (2015). Preclinical development of an anti-5T4 antibody-drug conjugate: pharmacokinetics in mice, rats, and NHP and tumor/tissue distribution in mice. Bioconjug Chem 26:2223–32.
   PubMed Web of Science ®Google Scholar
• Lee D, Sung ES, Ahn JH, et al. (2015). Development of antibody-based c-Met inhibitors for targeted cancer therapy. Immunotargets Ther 4:35–44.
   PubMed Web of Science ®Google Scholar
• Liu JF, Moore KN, Birrer MJ, et al. (2016). Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann Oncol 27:2124–30.
   PubMed Web of Science ®Google Scholar
• McNeil BK, Sorbellini M, Grubb RL, et al. (2014). Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladder. J Transl Med 12:199–05.
   PubMed Web of Science ®Google Scholar
• Mo HN, Liu P. (2017). Targeting MET in cancer therapy. Chronic Dis Transl Med 3:148–53.
   PubMedGoogle Scholar
• Parikh PK, Ghate MD. (2018). Recent advances in the discovery of small molecule c-Met kinase inhibitors. Eur J Med Chem 143:1103–38.
   PubMed Web of Science ®Google Scholar
• Pasquini G, Giaccone G. (2018). C-MET inhibitors for advanced non-small cell lung cancer. Expert Opin Investig Drugs 27:363–75.
   PubMed Web of Science ®Google Scholar
• Saber H, Leighton JK. (2015). An FDA oncology analysis of antibody-drug conjugates. Regul Toxicol Pharmacol 71:444–52.
   PubMed Web of Science ®Google Scholar
• Shen BQ, Bumbaca D, Saad O, et al. (2012). Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism. Curr Drug Metab 13:901–10.
   PubMed Web of Science ®Google Scholar
• Sheridan C. (2014). Genentech to salvage anti-MET antibody with subgroup analysis. Nat Biotechnol 32:399–400.
   PubMed Web of Science ®Google Scholar
• Strickler JH, Nemunaitis JJ, Weekes CD, et al. (2016). Phase 1, open-label, dose-escalation and expansion study of ABBV-399, an antibody drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors. J Clin Oncol 34:2510.
   Web of Science ®Google Scholar
• Wang H, Rangan VS, Sung MC, et al. (2016). Pharmacokinetic characterization of BMS-936561, an anti-CD70 antibody-drug conjugate, in preclinical animal species and prediction of its pharmacokinetics in humans. Biopharm Drug Dispos 37:93–106.
   PubMed Web of Science ®Google Scholar
• Weekes CD, Lamberts LE, Borad MJ, et al. (2016). Phase I study of DMOT4039A, an antibody-drug conjugate targeting mesothelin, in patients with unresectable pancreatic or platinum-resistant ovarian cancer. Mol Cancer Ther 15:439–47.
   PubMed Web of Science ®Google Scholar
• Williams SP. (2012). Tissue distribution studies of protein therapeutics using molecular probes: molecular imaging. AAPS J 14:389–99.
   PubMed Web of Science ®Google Scholar
• Xu S. (2015). Internalization, trafficking, intracellular processing and actions of antibody-drug conjugates. Pharm Res 32:3577–83.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xia M, Jin K, et al. (2018). Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol Cancer 17:45–58.
   PubMed Web of Science ®Google Scholar